<i>Lactobacillus fermentum</i> Improves Tacrolimus‐Induced Hypertension by Restoring Vascular Redox State and Improving eNOS Coupling

Toral, Marta; Romero, Miguel; Rodríguez-Nogales, Alba; Jiménez, Rosario; Robles-Vera, Iñaki; Algieri, Francesca; Chueca, Natalia; Sánchez, Manuel; Visitación, Néstor de la; Olivares, Mónica; García, Féderico; Pérez‐Vizcaíno, Francisco; Gálvez, Júlio; Duarte, Juan

doi:10.1002/mnfr.201800033

Cited by 77 publications

(89 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Changes in bacteria composition associated with hypertension are followed by alterations in the levels of bacterial metabolic products (Kim, et al, 2018). This concept is corroborated by data from several studies in hypertensive models that demonstrated higher F/B ratio in affected hosts (Yang, et al, 2015;Marques, et al, 2017;Toral, et al, 2018). Furthermore, fibre-rich diets or magnesium acetate and oral minocycline supplementation could restore gut microbiota homeostasis, reduce the F/B ratio and attenuate BP levels (Yang, et al, 2015;Marques, et al, 2017).…”

Section: Hypertensionmentioning

confidence: 73%

The gut microbiota and its interactions with cardiovascular disease

Wang

Feng

et al. 2020

Microbial Biotechnology

115

View full text Add to dashboard Cite

Summary The intestine is colonized by a considerable community of microorganisms that cohabits within the host and plays a critical role in maintaining host homeostasis. Recently, accumulating evidence has revealed that the gut microbial ecology plays a pivotal role in the occurrence and development of cardiovascular disease (CVD). Moreover, the effects of imbalances in microbe–host interactions on homeostasis can lead to the progression of CVD. Alterations in the composition of gut flora and disruptions in gut microbial metabolism are implicated in the pathogenesis of CVD. Furthermore, the gut microbiota functions like an endocrine organ that produces bioactive metabolites, including trimethylamine/trimethylamine N‐oxide, short‐chain fatty acids and bile acids, which are also involved in host health and disease via numerous pathways. Thus, the gut microbiota and its metabolic pathways have attracted growing attention as a therapeutic target for CVD treatment. The fundamental purpose of this review was to summarize recent studies that have illustrated the complex interactions between the gut microbiota, their metabolites and the development of common CVD, as well as the effects of gut dysbiosis on CVD risk factors. Moreover, we systematically discuss the normal physiology of gut microbiota and potential therapeutic strategies targeting gut microbiota to prevent and treat CVD.

show abstract

Section: Hypertensionmentioning

confidence: 73%

The gut microbiota and its interactions with cardiovascular disease

Wang

Feng

et al. 2020

Microbial Biotechnology

115

View full text Add to dashboard Cite

show abstract

“…Descending thoracic aortic rings were resected from the animals and were suspended in a wire myograph (model 610M; Danish Myo Technology, Hinnerup, Denmark) for isometric tension measurement as previously described (22). The organ chamber was filled with Krebs solution (composition in mM: 118 NaCl, 4.75 KCl, 25 NaHCO 3 , 1.2 MgSO 4 , 2 CaCl 2 , 1.2 KH 2 PO 4 , and 11 glucose) at 37°C and gassed with 95% O 2 and 5% CO 2 (pH ;7.4).…”

Section: Vascular Reactivity Studiesmentioning

confidence: 99%

“…The lymphocytes and splenocytes were then fixed, permeabilized, and intracellular staining was conducted with mAbs anti-FoxP3 (PE, clone FJK-16s; Thermo Fisher Scientific), anti-IL-17a (PE-Cy7, clone eBio17B7; Thermo Fisher Scientific), and anti-IFN-g (Alexa Fluor 488, clone XMG1.2; Thermo Fisher Scientific) for 30 min at 4°C in the dark. Data collection was performed using a flow cytometer Canto II (BD Biosciences) as previously described (16,22). Supplemental Figure S1 illustrates the gating strategy that was applied.…”

Section: Flow Cytometrymentioning

confidence: 99%

“…Therefore, this strain is a good candidate for functional food and pharmaceutical products. In addition, this probiotic strain reduced BP in spontaneously hypertensive rats (21) and in hypertensive mice induced by tacrolimus (22), improving gut barrier function and T helper cell (T h )17/regulatory T cell (T reg ) balance in mesenteric lymph nodes (23). Therefore, in the present study, we tested a hypothesis, posing that the treatment with the probiotic LC40 might ameliorate disease activity and cardiovascular complications through the modulation of the composition of intestinal microbiota and the immune system in female NZBWF1 mice.…”

mentioning

confidence: 96%

See 1 more Smart Citation

Lactobacillus fermentum CECT5716: a novel alternative for the prevention of vascular disorders in a mouse model of systemic lupus erythematosus

et al. 2019

Self Cite

View full text Add to dashboard Cite

The aim of the present study was to examine whether the immune‐modulatory bacteria Lactobacillus fermentum CECT5716 (LC40) ameliorates disease activity and cardiovascular complications in a female mouse model of lupus. Eighteen‐week‐old NZBWF1 [systemic lupus erythematosus (SLE)] and NZW/LacJ (control) mice were treated with vehicle or LC40 (5 × 108 colony‐forming units/d) for 15 wk. LC40 treatment reduced lupus disease activity, blood pressure, cardiac and renal hypertrophy, and splenomegaly in SLE mice. LC40 reduced the elevated T, B, regulatory T cells (Treg), and T helper (Th)‐1 cells in mesenteric lymph nodes of lupus mice. LC40 lowered the higher plasma concentration of proinflammatory cytokines observed in lupus mice. Aortas from SLE mice showed reduced endothelium‐dependent vasodilator responses to acetylcholine. Endothelial dysfunction found in SLE is related to an increase of both NADPH oxidase‐driven superoxide production and eNOS phosphorylation at the inhibitory Thr495. These activities returned to normal values after a treatment with LC40. Probiotic administration to SLE mice reduced plasma LPS levels, which might be related to an improvement of the gut barrier integrity. LC40 treatment increases the Bifidobacterium count in gut microbiota of SLE mice. In conclusion, our findings identify the gut microbiota manipulation with LC40 as an alternative approach to the prevention of SLE and its associated vascular damage.—Toral, M., Robles‐Vera, I., Romero, M., de la Visitación, N., Sánchez, M., O'Valle, F., Rodriguez‐Nogales, A., Gálvez, J., Duarte, J., Jiménez, R. Lactobacillus fermentum CECT5716: a novel alternative for the prevention of vascular disorders in a mouse model of systemic lupus erythematosus. FASEB J. 33, 10005–10018 (2019). http://www.fasebj.org

show abstract

“…The probiotic kefir also improved endothelial dysfunction in spontaneously hypertensive rats by decreasing ROS production, increasing NO bioavailability and restoring the recruitment of endothelial progenitor cells . Similarly, Lactobacillus fermentum improved tacrolimus‐induced endothelial dysfunction by reducing vascular oxidative stress and inflammation . The beneficial actions of probiotics on endothelial dysfunction has also been seen in some human studies .…”

Section: Probiotics and Endothelial Dysfunctionmentioning

confidence: 99%

The Potential of Probiotics in the Prevention and Treatment of Atherosclerosis

O'Morain

Ramji

2019

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Atherosclerosis, the underlying cause of cardiovascular diseases such as myocardial infarction, cerebrovascular accident, and peripheral vascular disease, is the leading cause of global mortality. Current therapies against atherosclerosis, which mostly target the dyslipidemia associated with the disease, have considerable residual risk for cardiovascular disease together with various side effects. In addition, the outcomes from clinical trials on many promising pharmaceutical agents against atherosclerosis (e.g., low‐dose methotrexate, inhibitors against cholesteryl ester transfer protein) have been disappointing. Nutraceuticals such as probiotic bacteria have, therefore, generated substantial recent interest for the prevention of atherosclerosis and potentially as add‐ons with current pharmaceutical drugs. This review will discuss the current understanding of the anti‐atherogenic actions of probiotics from preclinical and clinical studies together with their potential underlying mechanisms of action.

show abstract

Lactobacillus fermentum Improves Tacrolimus‐Induced Hypertension by Restoring Vascular Redox State and Improving eNOS Coupling

Cited by 77 publications

References 59 publications

The gut microbiota and its interactions with cardiovascular disease

The gut microbiota and its interactions with cardiovascular disease

Lactobacillus fermentum CECT5716: a novel alternative for the prevention of vascular disorders in a mouse model of systemic lupus erythematosus

The Potential of Probiotics in the Prevention and Treatment of Atherosclerosis

Contact Info

Product

Resources

About